Recent Updates
Recently added Catalysts
INDV Positive Sentiment Score: 75/100

Indivior To Participate in Upcoming Investor Events Slough, UK, and Richmond, VA

Key Takeaway: Indivior PLC has announced its participation in upcoming investor events, including the Craig-Hallum Institutional Investor Conference in Minneapolis and the Jefferies Global Healthcare Conference in New York City. The CEO, Mark Crossley, will host a presentation at the Jefferies conference, which will be publicly available. Indivior focuses on developing medicines for substance use disorders and aims to provide access to evidence-based treatment worldwide. The company is headquartered in Richmond, VA and employs over 1,100 people globally.

Market Sentiment Analysis

POSITIVE FACTORS

  • Indivior is actively engaging with investors through upcoming events.
  • The company is focused on transforming substance use disorders into recognized chronic diseases.
  • Indivior's management is presenting at prestigious healthcare conferences.

Full Press Release Details

Indivior To Participate in Upcoming Investor Events
Slough, UK, and Richmond, VA, May 16, 2024 - Indivior PLC (LSE/NASDAQ: INDV) today announced
that it will participate in the following investor
Craig-Hallum Institutional Investor Conference - Minneapolis,
Indivior Management will host 1x1 / Group meetings
on Wednesday May 29th,
2024. Interested investors should contact their Craig-Hallum
representative to schedule a meeting.
Jefferies Global Healthcare
Conference - New York City, NY
Mark Crossley, Chief Executive Officer, will host
a presentation on Wednesday June 5th,
2024 at 8:30 a.m. US EST. The presentation will be publicly
available and can be viewed using the following
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat substance use
disorders (SUD) and serious mental illnesses. Our vision is that
all patients around the world will have access to evidence-based
treatment for the chronic conditions and co-occurring disorders of
SUD. Indivior is dedicated to transforming SUD from a global human
crisis to a recognized and treated chronic disease. Building on its
global portfolio of opioid use disorder treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and cooccurring disorders of SUD. Headquartered in the
United States in Richmond, VA, Indivior employs more than 1,100
individuals globally and its portfolio of products is available in
37 countries worldwide. Visit www.indivior.com to learn
more. Connect with Indivior on LinkedIn by
Vice President, Investor Relations
Tel: 804-402-7123 or jason.thompson@indivior.com
Director, Investor Relations
Tel: 804-263-3978 or timothy.owens@indivior.com

Frequently Asked Questions

When is Indivior participating in the Craig-Hallum Conference?

Indivior will participate in the Craig-Hallum Conference on May 29, 2024.

Who will present at the Jefferies Global Healthcare Conference?

Mark Crossley, the CEO, will present at the Jefferies Conference on June 5, 2024.

What is Indivior's primary focus?

Indivior focuses on developing medicines for substance use disorders and mental illnesses.

Where is Indivior headquartered?

Indivior is headquartered in Richmond, VA, United States.

How many countries does Indivior operate in?

Indivior's products are available in 37 countries worldwide.

Last updated: May 16, 2024